Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth

Li,Hao; Xu,Kanghe; Pian,Guangzhe; Sun,Shu

doi:10.3892/ol.2019.10810

Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth

Authors:
- Hao Li
- Kanghe Xu
- Guangzhe Pian
- Shu Sun
View Affiliations

Affiliations: Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China
Published online on: September 5, 2019 https://doi.org/10.3892/ol.2019.10810
Pages: 4735-4743
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An antimalarial medication, artesunate (Art), has exhibited promising anticancer effects with excellent tolerability in various types of cancer, suggesting that it has the potential to be used in combination with sorafenib (Sora) in hepatocellular carcinoma (HCC) treatment. To determine the potency of this combination, the present study attempted to quantitatively measure the dose‑effect relationship of each drug alone and in combination in liver cancer cells in vitro using Calcusyn software. Cell growth inhibition was determined using the CyQUANT proliferation assay in two liver cancer cell lines, HepG2 and Huh7. Drug combination and reduction indices and isobologram plots were used to assess drug interactions. Cell apoptosis was evaluated by measurements of the proportion of cells in the sub G0/G1 phase of the cell cycle, and determination of protein expression levels of cleaved poly ADP ribose polymerase and caspase‑9. Additionally, a cell migration assay was conducted using Essen ImageLock plates with an IncuCyte Zoom imaging system. The results of the present study revealed that the inhibitory effect of Sora on cell growth was synergistically enhanced by the combination with Art in HepG2 and Huh7 cells. The combination index and dose reduction index were specific to each cell line. Furthermore, combination at a fixed ratio presented mutual enhancement with respect to apoptosis induction and suppression of in vitro liver cancer cell migration. Therefore, considering the low toxicity and well‑defined clinical characteristics of Art, combination of Sora and Art may present an attractive therapeutic option in the development of clinical trials for HCC treatment.

View Figures

View References

1	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
2	Sun W and Cabrera R: Systemic treatment of patients with advanced, unresectable hepatocellular carcinoma: Emergence of therapies. J Gastrointest Cancer. 49:107–115. 2018. View Article : Google Scholar : PubMed/NCBI
3	Dondorp A, Nosten F, Stepniewska K, Day N and White N; South East Asian Quinine Artesunate Malaria (SEAQUAMAT) Group, : Artesunate versus quinine for treatment of severe falciparum malaria: A randomised trial. Lancet. 366:717–725. 2005. View Article : Google Scholar : PubMed/NCBI
4	Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI
5	Crespo-Ortiz MP and Wei MQ: Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012:2475972012. View Article : Google Scholar : PubMed/NCBI
6	Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC and Pullarkat V: Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. Leuk Res. 59:124–135. 2017. View Article : Google Scholar : PubMed/NCBI
7	Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T and Kumar D: A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine. 2:82–90. 2015. View Article : Google Scholar : PubMed/NCBI
8	Chauhan AK, Min KJ and Kwon TK: RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma Caki cells. Mol Cell Biochem. 435:15–24. 2017. View Article : Google Scholar : PubMed/NCBI
9	Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/beta-catenin signaling. Oncotarget. 7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhang CZ, Zhang H, Yun J, Chen GG and Lai PB: Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol. 83:1278–1289. 2012. View Article : Google Scholar : PubMed/NCBI
11	Greenshields AL, Shepherd TG and Hoskin DW: Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 56:75–93. 2017. View Article : Google Scholar : PubMed/NCBI
12	Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS and Fleckenstein L: Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 10:2632011. View Article : Google Scholar : PubMed/NCBI
13	Efferth T, Giaisi M, Merling A, Krammer PH and Li-Weber M: Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One. 2:e6932007. View Article : Google Scholar : PubMed/NCBI
14	Wang B, Hou D, Liu Q, Wu T, Guo H, Zhang X, Zou Y, Liu Z, Liu J, Wei J, et al: Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther. 16:1548–1556. 2015. View Article : Google Scholar : PubMed/NCBI
15	Efferth T: Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib. Phytomedicine. 37:58–61. 2017. View Article : Google Scholar : PubMed/NCBI
16	Nunes JJ, Pandey SK, Yadav A, Goel S and Ateeq B: Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens. Neoplasia. 19:333–345. 2017. View Article : Google Scholar : PubMed/NCBI
17	Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens A, Verhelst X, et al: Therapeutic effects of artesunate in hepatocellular carcinoma: Repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 26:861–870. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ilamathi M, Santhosh S and Sivaramakrishnan V: Artesunate as an anti-cancer agent targets stat-3 and favorably suppresses hepatocellular carcinoma. Curr Top Med Chem. 16:2453–2463. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chen HH, Zhou HJ, Wu GD and Lou XE: Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 71:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
20	Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA and Montalto G: Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 11:2843–2855. 2012. View Article : Google Scholar : PubMed/NCBI
21	Liu J, Liu Y, Meng L, Ji B and Yang D: Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells. Int J Med Sci. 14:523–529. 2017. View Article : Google Scholar : PubMed/NCBI
22	Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Mayanja-Kizza H, Katabira E, Hanpithakpong W, Obua C, Pakker N, Lindegardh N, et al: Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar J. 11:1322012. View Article : Google Scholar : PubMed/NCBI
23	Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S and Alberts SR: Phase I/II randomized trial of sorafenib and bevacizumab as first-line therapy in patients with locally advanced or metastatic hepatocellular carcinoma: North central cancer treatment group trial N0745 (Alliance). Target Oncol. 12:201–209. 2017. View Article : Google Scholar : PubMed/NCBI
24	Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI
25	Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, et al: Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 69:353–358. 2018. View Article : Google Scholar : PubMed/NCBI
26	Tran BN, Nguyen HT, Kim JO, Yong CS and Nguyen CN: Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. Drug Dev Ind Pharm. 43:1952–1962. 2017. View Article : Google Scholar : PubMed/NCBI
27	Goswami U, Kandimalla R, Kalita S, Chattopadhyay A and Ghosh SS: Polyethylene glycol-encapsulated histone deacetylase inhibitor drug-composite nanoparticles for combination therapy with artesunate. ACS Omega. 3:11504–11516. 2018. View Article : Google Scholar : PubMed/NCBI
28	Efferth T: Cancer combination therapies with artemisinin-type drugs. Biochem Pharmacol. 139:56–70. 2017. View Article : Google Scholar : PubMed/NCBI